CD19 and Miyoshi myopathy: Here we showed that in spite of being significantly more sensitive than cytology to detect MRD in MM, FCM—measured by the identification of plasma cells CD45−/dim CD138+, CD38+high, and CD19− CD56+ [13–15, 23]—did not predict for relapse or death from MM in our group of patients.